Guidance For Industry - PQR

©2017 Transparency Market Research, All Rights Reserved
Anti-Venom Market: Global Industry, Size, Share, Growth,

Trends, and Forecast, 2017–2025
April 2017

Section 01
Preface
©2017 Transparency Market Research, All Rights Reserved 2

Table Of Content (1/12)

Content
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Anti-Venom Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
3

Content
4.6. Global Anti-Venom Market Analysis and Forecasts, 2015–2025
4.7. Polyvalent Anti-Venom Development: Overview
4.8. Scorpion Anti-Venom Development: Overview
5. Global Anti-Venom Market Analysis and Forecasts, By Anti-Venom Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value Forecast By Anti-Venom Type , 2015–2025
5.4.1. Monovalent
5.4.2. Polyvalent
5.5. Market Attractiveness By Anti-Venom Type
5.4. Key Trends
6. Global Anti-Venom Market Analysis and Forecasts, By Product Type
4

Content
6.3. Key Trends
6.4. Market Value Forecast By Product Type, 2015–2025
6.4.1. Snake Anti-Venom
6.4.2. Scorpion Anti-Venom
6.2.3 Spider Anti-Venom
6.2.4. Others
6.5. Market Attractiveness By Application
7. Global Anti-Venom Market Analysis and Forecasts, By Distribution Channel
7.3. Key Trends
7.4. Market Value Forecast By Distribution Channel, 2015–2025
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Ambulatory Surgical Centers
7.5. Market Attractiveness By Distribution Channel
5

Content
8. Global Anti-Venom Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. Asia Pacific
8.2.2. Middle East and Africa
8.2.3. Latin America
8.2.4. North America
8.2.5. Europe
8.3. Market Attractiveness By Country/Region
9. Asia Pacific Anti-Venom Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2.1. Monovalent
9.2.2. Polyvalent
6

Content
9.2. Market Value Forecast By Product Type , 2015–2025
9.2.3. Spider Anti-Venom
9.2.4. Others
9.4.1. Hospitals
9.4.2. Clinics
9.5. Market Value Forecast By Country , 2015–2025
9.5.1. India
9.5.2. China
9.5.3. Japan
9.5.4. Australia & New Zealand
9.5.5. Rest of APAC
9.6 Market Attractiveness Analysis
7

Content
9.6.1. By Anti-Venom Type
9.6.2. By Product Type
9.6.3. By Distribution Channel
9.6.4. By Country
10. Middle East & Africa Anti-Venom Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2.1. Monovalent
10.2.2. Polyvalent
10.2.4. Others
8

Content
10.4.1. Hospitals
10.4.2. Clinics
10.5.1. South Africa
10.5.2. Saudi Arabia
10.5.3. Rest of MEA
10.6.4. By Country
11. Latin America Anti-Venom Market Analysis and Forecast
11.1. Introduction
9

Content
11.2.1. Monovalent
11.2.2. Polyvalent
11.2.4. Others
11.4.1. Hospitals
11.4.2. Clinics
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of LA
11.6. Market Attractiveness Analysis
10

Content
11.6.4. By Country
12. North America Anti-Venom Market Analysis and Forecast
12.1. Introduction
12.2.1. Monovalent
12.2.2. Polyvalent
12.2.4. Others
11

Content
12.4.1. Hospitals
12.4.2. Clinics
12.5.1. The U.S
12.5.2. Canada
12.6.4. By Country
13. Europe Anti-Venom Market Analysis and Forecast
13.1. Introduction
13.2.1. Monovalent
13.2.2. Polyvalent
12

Content
13.2.4. Others
13.4.1. Hospitals
13.4.2. Clinics
13.5.1. India
13.5.2. China
13.5.3. Japan
13.5.4. Australia & New Zealand
13.5.5. Rest of APAC
13

Content
13.6.4. By Country
14. Company Profiles
14.1. Competition Matrix
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. CSL Behring LLC
14.2.2. Bharat Serums and Vaccines Ltd.
14.2.3. Haffkine Bio-pharmaceutical Corporation Ltd.
14.2.4. VACSERA
14.2.5. Vins Bioproducts Limited
14.2.6. Rare Disease Therapeutics, Inc.
14.2.7. BTG International Ltd.
14.2.8. Instituto Butantan
14.2.9. South African Vaccine Producers (Pty) Ltd.
12.2.10. Other Prominent Players
14
List of Figures (1/6)

List of Figures
Figure 01: Research Methodology
Figure 02: Global Anti-venom Market Value Share Analysis, by Anti-Venom Type, 2017 and 2025
Figure 03: Global Monovalent Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 04: Global Polyvalent Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 05: Global Anti-venom Market Attractiveness Analysis, by Anti-Venom Type
Figure 06: Global Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 07: Global Snake Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 08: Global Scorpion Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 09: Global Spider Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 10: Global Other Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 11: Global Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 13: Global Anti-venom Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 14: Global Hospitals Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 15: Global Clinics Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 16: Global Ambulatory Surgical Centers Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
15

List of Figures
Figure 17: Global Other Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 18: Global Anti-Venom Market Attractiveness Analysis, by Distribution Channel
Figure 19: Global Anti-Venom Market Value Share Analysis, by Region, 2017 and 2025
Figure 20: Asia Pacific Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 21: Middle East & Africa Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 22: Latin America Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 23: North America Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 24: Europe Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 25: Global Anti-Venom Market Attractiveness Analysis, by Region
Figure 26: Asia Pacific Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 27: Asia Pacific Anti-Venom Market Attractiveness Analysis, by Country
Figure 28: Asia Pacific Anti-venom Market Value Share Analysis, by Anti-Venom Type, 2017 and 2025
Figure 29: Asia Pacific Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 30: Asia Pacific Anti-venom Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 31: Asia Pacific Anti-venom Market Value Share Analysis, by Country, 2017 and 2025
Figure 32: Asia Pacific Anti-venom Market Attractiveness Analysis, by Anti-Venom Type
16

List of Figures
Figure 33: Asia Pacific Anti-venom Market Attractiveness Analysis, by Product Type
Figure 34: Asia Pacific Anti-venom Market Attractiveness Analysis, by Distribution Channel
Figure 35: Asia Pacific Anti-venom Market Attractiveness Analysis, by Country
Figure 36: Middle East & Africa Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 37: Middle East & Africa Anti-Venom Market Attractiveness Analysis, by Country
Figure 38: Middle East & Africa Anti-venom Market Value Share Analysis, by Anti-Venom Type, 2017 and 2025
Figure 39: Middle East & Africa Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 40: Middle East & Africa Anti-venom Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 41: Middle East & Africa Anti-venom Market Value Share Analysis, by Country, 2017 and 2025
Figure 42: Middle East & Africa Anti-venom Market Attractiveness Analysis, by Anti-Venom Type
Figure 43: Middle East & Africa Anti-venom Market Attractiveness Analysis, by Product Type
Figure 44: Middle East & Africa Anti-venom Market Attractiveness Analysis, by Distribution Channel
Figure 45: Middle East & Africa Anti-venom Market Attractiveness Analysis, by Country
Figure 46: Latin America Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 47: Latin America Anti-Venom Market Attractiveness Analysis, by Country
Figure 48: Latin America Anti-venom Market Value Share Analysis, by Anti-Venom Type, 2017 and 2025
17

List of Figures
Figure 49: Latin America Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 50: Latin America Anti-venom Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 51: Latin America Anti-venom Market Value Share Analysis, by Country, 2017 and 2025
Figure 52: Latin America Anti-venom Market Attractiveness Analysis, by Anti-Venom Type
Figure 53: Latin America Anti-venom Market Attractiveness Analysis, by Product Type
Figure 54: Latin America Anti-venom Market Attractiveness Analysis, by Distribution Channel
Figure 55: Latin America Anti-venom Market Attractiveness Analysis, by Country
Figure 56: North America Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 57: North America Anti-Venom Market Attractiveness Analysis, by Country
Figure 58: North America Anti-venom Market Value Share Analysis, by Anti-Venom Type, 2017 and 2025
Figure 59: North America Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 60: North America Anti-venom Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 61: North America Anti-venom Market Value Share Analysis, by Country, 2017 and 2025
Figure 62: North America Anti-venom Market Attractiveness Analysis, by Anti-Venom Type
Figure 63: North America Anti-venom Market Attractiveness Analysis, by Product Type
Figure 64: North America Anti-venom Market Attractiveness Analysis, by Distribution Channel
18

List of Figures
Figure 65: North America Anti-venom Market Attractiveness Analysis, by Country
Figure 66: Europe Anti-Venom Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 67: Europe Anti-Venom Market Attractiveness Analysis, by Country
Figure 68: Europe Anti-venom Market Value Share Analysis, by Anti-Venom Type, 2017 and 2025
Figure 69: Europe Anti-venom Market Value Share Analysis, by Product Type, 2017 and 2025
Figure 70: Europe Anti-venom Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 71: Europe Anti-venom Market Value Share Analysis, by Country, 2017 and 2025
Figure 72: Europe Anti-venom Market Attractiveness Analysis, by Anti-Venom Type
Figure 73: Europe Anti-venom Market Attractiveness Analysis, by Product Type
Figure 74: Europe Anti-venom Market Attractiveness Analysis, by Distribution Channel
Figure 75: Europe Anti-venom Market Attractiveness Analysis, by Country
Figure 76: Breakdown of Net Sales (2015), by Segments: CSL Behring
Figure 77: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: CSL Behring
Figure 78: Breakdown of Net Sales (2015), by Segments: Bharat Serums and Vaccines Ltd
Figure 79: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Bharat Serums and Vaccines Ltd
Figure 80: Breakdown of Net Sales (2015), by Segments: Haffkine Bio-Pharmaceutical Corporation Ltd
19

List of Figures
Figure 81: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Haffkine Bio-Pharmaceutical Corporation Ltd
Figure 82: Breakdown of Net Sales (2015), by Segments: Vacsera
Figure 83: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Vacsera
Figure 84: Breakdown of Net Sales (2015), by Segments: Vins Bioproducts Limited
Figure 85: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Vins Bioproducts Limited
Figure 86: Breakdown of Net Sales (2015), by Segments: Rare Disease Therapeutics, Inc.
Figure 87: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Rare Disease Therapeutics, Inc.
Figure 88: Breakdown of Net Sales (2015), by Segments: BTG International Ltd.
Figure 89: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: BTG International Ltd.
Figure 90: Breakdown of Net Sales (2015), by Segments: Instituto Butantan
Figure 91: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Instituto Butantan
Figure 92: Breakdown of Net Sales (2015), by Segments: South African Vaccine Producers (Pty) Ltd.
Figure 93: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: South African Vaccine Producers (Pty) Ltd.
Figure 94: Breakdown of Net Sales (2015), by Segments: Micropharm LLC.
Figure 95: Revenue (US$ Bn) & Y-o-Y Growth (%), 2012–2015: Micropharm LLC.
20
List of Table (1/2)

List of Table
Table 01: Global Anti-venom Market Size (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025
Table 02: Global Anti-venom Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 03: Global Anti-venom Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 04: Global Anti-venom Market Size (US$ Mn) Forecast, by Region,
Table 05: Asia Pacific Market Size (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025
Table 06: Asia Pacific Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 07: Asia Pacific Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 08: Asia Pacific Anti-venom Market Size (US$ Mn) Forecast, by Country,
Table 09: Middle East & Africa Market Size (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025
Table 10: Middle East & Africa Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 11: Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 12: Middle East & Africa Anti-venom Market Size (US$ Mn) Forecast, by Country,
21
List of Table (2/2)

List of Table
Table 13: Latin America Market Size (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025
Table 14: Latin America Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 15: Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 16: Latin America Anti-venom Market Size (US$ Mn) Forecast, by Country,
Table 17: North America Market Size (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025
Table 18: North America Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 19: North America Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 20: North America Anti-venom Market Size (US$ Mn) Forecast, by Country,
Table 21: Europe Market Size (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025
Table 22: Europe Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
Table 23: Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 24: Europe Anti-venom Market Size (US$ Mn) Forecast, by Country
22
Preface (1/2)
Report Scope and Market Segmentation
Anti-Venom Type
 This report studies the current as well as future
prospects of the global anti-venom market  Monovalent
 Stakeholders of this report include companies  Polyvalent
and intermediaries engaged in the manufacture
and commercialization of various anti-venom
products as well as new entrants planning to
enter this market
Anti-Venom MARKET
 This report comprises an elaborate executive
summary along with a market snapshot
REPORT SCOPE
Product Type
providing overall information of various
segments considered in the scope of the study.  Snake Anti-Venom
This section provides the overall information  Scorpion Anti-Venom
and data analysis of the global anti-venom  Spider Anti-Venom
market with respect to the leading market  Others
segments based on major products,
applications, and regions.
 The global anti-venom market has been studied
based on major product segments and their
regional as well as national markets Region
 Market revenue (in terms of US$ Mn) for the
period from 2015 to 2025 along with the  North America
compound annual growth rate (CAGR %) from  Latin America
2017 to 2025 are provided for all segments,  Europe
considering 2016 as the base year and 2015 as  Asia Pacific
the historical year  Middle East and Africa
23
Preface (2/2)
Research Highlights
Research Objectives Key Questions Answered
 The primary objective of the research is to provide the market  What is the sales/revenue generated by anti-venom products
estimate and forecast for anti-venom in terms of value (US$ across all the regions during the forecast period?
Mn) for the period 2015–2025
 What are the key trends in the anti-venom market?
 The secondary objectives include analysing:
 What are the major drivers, restraints, and opportunities in the
 Market with the maximum potential for investment and growth
market?
 Products with the highest growth rate during the forecast period
 Demand for anti-venom across each region  Which region is set to expand at the highest CAGR during the
forecast period?
 Leading strategies adopted by key players in the market
 Competitive position of leading players in the market  Which segment will have the highest revenue globally in 2025
and which product will expand at the highest CAGR during the
forecast period?
24
Section 02
Assumptions and Research Methodology
25
Figure 1: Research Methodology
Anti-Venom Market
Secondary Research Primary Research
(US$ Mn)
North Latin
Europe Asia Pacific MEA
America America
Mergers and
acquisitions Cost factor
Incidence of Anti-Venom Market Economic

animal bites Indicators
Pipeline anti- Recombinant anti-

venom venom
Anti-Venom Market Analysis and Forecast,

(US$ Mn, CAGR %), 2017–2025
Product Overview
 Immunoglobulins or antidotes that provide protection against exposure or bite of poisonous or venomous
animals are referred as anti-venom, which is obtained or extracted from an animal that has been immunized
against appropriate venom or toxin
Product Definition  Anti-venoms play a crucial role in preventing or reversing the envenoming effect of poisonous snakes,
scorpions, spiders, fish, etc., thereby reducing mortality and morbidity
 Anti-venom is expected to be administered within four hours of envenomation, but can also be given before
24 hours, while its dosage depends upon the degree or extent of envenomation
 North America
 Latin America
Key Regions  Europe
 Asia Pacific
 Middle East & Africa
 Monovalent anti-venoms are specific to species, thus providing protection against single species, while
polyvalent anti-venoms are effective against several species of animals
Key Product Type
 Snake polyvalent anti-venom is the most widely used anti-venom due to high incidence of snake bites as
compared to other species of animals or insects
 CSL Behring
 Bioclon
Key Players  Serum Institute of India Limited
 Bharat Serums And Vaccines Limited
 South African Vaccine Producers
27
Timeline for Anti-Venom Development (1/2)

Felice Fonatana verified viper and non-poisonous snake’s Lucien Bonaparte identified a protein named
1781 immunity against viper venom 1841-43 echidnine/viperine in vipera berus venom, which was
01
found to be same as digestive enzyme
Domenico Fornara successfully immunized dogs against Henry Sewall immunized pigeons against rattle snake
1887
07
1877 frog venom (Crotalus) by injecting venom doses at increasing
concentrations
Maurice Kaufmann developed theory stating that Tetanus anti-toxins was developed by Behring and
1889 1890
06
inoculation of venom with increasing dose might confer Kitasato
degree of immunity against high doses of venom
03
05 041892
Calmette successfully extracted and stored snake venom Maurice Kaufmann proved that successive inoculation of
1891 venom in small amounts provides resistance, but is
incapable to confer immunity against envenomation
Development of first anti-venom in rabbits by Calmette Calmette developed first commercial anti-venom by
1894 1895 immunizing horses against Indian cobra (Naja naja)
28
Key Industry Developments (1/2)

Dr. Vital Brazil proved that the anti-venom produced by Understanding the importance of polyspecific anti-
1897 Calmette for Indian cobra was not effective against the
Bothrops jararaca and Crotalus durissus terrificus, thus,
1901 venom, Dr. Vital Brazil injected mixtures of venom from
different species of snake to immunize horses and mules
demonstrated the species specificity of anti-venom for production of polyspecific anti-venom
Tidswell and Mastin developed first Australian Development of first anti-venom for human use
1901 experimental poison by immunizing horses with Notechis 1930
scutatus venom
1962
Development of polyspecific anti-venom
29
Timeline for Polyclonal Anti-Venom Development
Antibody Engineering Improved Immunization 2000 Immunization With Purified Toxins
Lyophilization 1990 Hybridoma Technology (improved

stability)
Safety 1970 Improved Purification
Fragmentation, with Pepsin or Papain F(ab)’2, Fab’ 1936 Improved Pharmacokinetics
Improved Specific Activity 1930 (NH4)2SO4 Precipitation
Anavenoms 1924 Improved Immunization
Developed by Calmette & Phisalix 1984 Serum Therapy
30
©2015 Future Market Insights, All Rights Reserved
Timeline for Scorpion Anti-Venom Development

1999 Mousli et al. developed murine monoclonal IgG derived first scorpion Aah toxin neutralizing scFv
First Scorpion toxin neutralizing recombinant Fab fragments

Selisko et al developed anti-Cn2 Aubrey et al. derived anti-Aahl, rFab from
2004 chimeric rFab murine monoclonal IgG
2005 Evolution of phage-displayed murine scFv against Cn2, Juare & Gonzalez et al.
Riano-Umbaria et al. isolated anti-Cn2 scFvs from naïve human libraries and maturation
2007 Juste et al. developed first murine tandem-scFv that provides protection against Aa venom
2008 Hmila et al. developed nanobody for neutralizing Aahl’
2010 Hmila et al. developed first camelid bispecific nanobody that neutralizes Aa venom
2011 Ben Abderrazeck et al. were successful in maturation and humanization of nanobodies
2012 Di Tommaso et al. provided first cocktail of diabodies to protect against Aa venom
Rodriguez-Rodriguez et al. were successful in in-vitro maturation and reformatting of human scFvs
31
Section 05
Market Dynamics
32
Drivers and Restraints Snapshot Analysis (1/1)

Drivers Restraints
 Improvement in snake identification techniques

 Worldwide neglect for immunotherapeutic
products
 Improved spending capacity and health care
infrastructure in emerging markets
 Rise in demand for plasma proteins  Variable and high costs of anti-venom
 Initiative to develop low cost treatment
 Inadequate financial support
 Initiatives for sufficient anti-venom supply
33
Drivers (1/3)
 After snake bite, it was extremely important to identify the snake positively, before the
advent of polyvalent anti-venom in 1969. Snake identification is crucially important for
Improvement in administration of appropriate anti-venom as anti-venom exhibits both species as well as
snake identification
regional specificity.
techniques
 Polyvalent anti-venom is available presently; however, treatment with monovalent anti-
venom is preferred as it is more efficient and less hazardous to patients
 Technological advancements have led to introduction of venom identification kits, which help
in accurate identification of snake type in less than 30 minutes
Improved spending
capacity and health
care infrastructure in
 Content
emerging markets
Scale of Impact : High Medium Low

34
Restraints (1/2)
 There is worldwide neglect for immunotherapeutic products which has resulted in shortage
Worldwide neglect of affordable, safe, and efficient snakebite therapy, especially in Africa
for  Snake bites, scorpion bites, and spider bites are the most neglected health problems across
immunotherapeutic the globe, as thousands of victims are reported to die or become maimed permanently
products
 Anti-venom in general is easily available in developed countries, while developing countries
in Asia and Africa where demand for anti-venom is high have less availability
Variable and high

costs of anti-venom
 Content
37
Opportunities
Research boosting novel anti-venom production Market opportunities in developing countries
 Scorpions and spiders are the most dangerous venomous animals to  Content
humans after snakes. A report published in the journal ‘Toxin’ in
2016 indicated existence of 10 million spider and 1 lakh scorpion
toxins. Hence, there is a need for development of anti-venom against
these medically important toxins of venomous animals.
 Effective treatment against the stings of scorpions and spiders
include parenteral administration of antisera or anti-venom.
Currently, only 20 anti-sera or anti-venoms of equine origin are
available against scorpion stings, out of which about 19 are for
human use and 1 for animal use.
 Therefore, research has been triggered on these scorpion and spider
toxins to be used for discovery of drug and novel structures of venom
receptors. This pool of available information on complete structure
of venom, estimate of toxicity, and bioinformatics data is being
employed in the development of novel anti-venom production with
modern tools
 For instance, in 2016, Rodriguez-Rodriguez et al. differentiated
between the medically significant as well as non-significant toxins
using toxicity scores of venoms in Centruroides scorpion. This is
expected to aid in the selection of toxins feasible for fast-track anti-
venom production and hence provides growth opportunities in the
anti-venom market during the forecast period.
39
Key Trends
Extensive research on recombinant anti-venom 1 Biotechnological approach for neglected venoms 2

 Currently available equine origin anti-venom contains large fractions  Content
of antibodies that are therapeutically irrelevant. These antibodies are
present in the anti-venom in response to the immune system of
animal that acts against wide range of antigens including bacteria and
viruses.
 To overcome this, research has been carried out to produce human
based mixture of antibodies designed in a way that would specifically
target the desired toxins. Development of recombinant anti-venom
would help complete elimination of non-specific or therapeutically
irrelevant proteins or antibodies, and thus reduce the side effects of
anti-venom treatment.
 Content
40
Section 06
Global Anti-Venom Market Analysis, by Anti-Venom

Type
41
Key Findings
Monovalent Anti-Venom Highlights

 In terms of revenue, the monovalent anti-  Content
venom segment contributed US$ XX Mn to the
global anti-venom market in 2016. The segment
is projected to expand at a CAGR of XX% during
the forecast period.
Polyvalent Anti-Venom Highlights

 In terms of revenue, the polyvalent anti-venom  Content
segment was valued at US$ XX Mn in 2016. It is
likely to expand at a CAGR of XX% from 2017 to
2025.
42
Introduction (2/2)
Global Anti-Venom Market, by Anti-
Venom Type
Monovalent Polyvalent
2016 (A): US$ XX Mn 2016 (A): US$ XX Mn

CAGR: XX% CAGR: XX%
(2017–2025) (2017–2025)
2025 (F): US$ XX Mn 2025 (F): US$ XX Mn
The monovalent anti-venom The polyvalent anti-venom segment

segment held XX% share of the accounted for XX% share of the anti-
global anti-venom market in 2016. It venom market in 2016. It is estimated to
is likely to expand at a CAGR of XX% expand at a CAGR of XX% during the
from 2017 to 2025. forecast period.
Source: TMR, 2017

43
Global Anti-Venom Market Value Share Analysis, by Anti-Venom Type

Content
Figure 02: Global Anti-venom Market Value Share Analysis, by

Anti-venom Type, 2016 and 2025 Analysis
  The polyvalent anti-venom segment accounted for XX% share

US$ XX Mn US$ XX Mn of the market in 2016. Its share is anticipated to increase to
XX% by 2025, expanding at a CAGR of XX% during the forecast
period.
 Content
2016A 2025F
Polyvalent Monovalent
Source: TMR, 2017

44
Global Anti-venom Market Forecast, by Anti-Venom Type

Content
Table 01: Global Anti-venom Market Value (US$ Mn) Forecast, by Anti-Venom Type, 2015–2025

CAGR
Anti-venom Type 2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F (2017–
2025)
Monovalent Anti-
Venom
XX XX XX XX XX XX XX XX XX XX XX XX%
Polyvalent Anti-
Venom
Total XX XX XX XX XX XX XX XX XX XX XX XX%
Source: TMR, 2017

45
Global Anti-venom Market Analysis, by Anti-Venom Type (1/1)

Content
Figure 03: Global Monovalent Anti-Venom Market Revenue

(US$ Mn), by Monovalent, 2015–2025 Analysis
 670 .0
3.5 0%
 In terms of revenue, the monovalent

570 .0
3.0 0%
segment was valued at US$ XX Mn in

Monovalent 470 .0
2.5 0%
2016. It is projected to reach US$ XX Mn

2.0 0%
by 2025, expanding at a CAGR of XX%

during the forecast period.
370 .0
1.5 0%
270 .0
 Content
1.0 0%
170 .0
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Value (US$ Mn) Y-o-Y Growth (%)
Figure 04: Global Polyvalent Anti-Venom Market Revenue

(US$ Mn), by Polyvalent, 2015–2025 Analysis
9.0 0%
 In terms of revenue, the polyvalent


2,5 30.0
8.0 0%
segment was valued at US$ XX Mn in

Polyvalent 2,0 30.0
7.0 0%
2016. It is estimated to reach US$ XX Mn
1,5 30.0
6.0 0% by 2025, expanding at a CAGR of XX%
5.0 0%
from 2017 to 2025.
1,0 30.0
530 .0
4.0 0%
 Content
3.0 0%
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Source: TMR, 2017

46
Global Anti-Venom Market Attractiveness Analysis, by Anti-venom Type

Content
Figure 05: Global Anti-Venom Market Attractiveness Analysis, by

Anti-Venom Type Analysis
  The XX segment is projected to be the most attractive product

2.5 segment in the global anti-venom market with a market
attractive index of XX. This segment is projected to expand at a
CAGR of XX% during the forecast period. It is likely to
2.0
dominated the market and account for XX% share by 2025.
 Content
1.5
CAGR Index
1.0
0.5
0.0
0.0 0.5 1.0 1.5 2.0
Market Share Index
Source: TMR, 2017

47
Key Trends
1 Preference for polyvalent anti-venom P 2 Expansion of regional market
 Many players in the industry are striving to expand their anti-  Content
venom production plants, which is too expensive. Thus, making
the final anti-venom product expensive. Therefore, steps are
taken to develop new cost-effective and specific anti-venoms
 For instance, polyspecific or polyvalent anti-venom was developed
by the collaboration of University of Peradeniya in Sri Lanka and
Instituto Clodomiro Picado (ICP) in Costa Rica
 This polyvalent anti-venom is in clinical trials funded by National
Research Council of Sri Lanka, and is effective against hump-nosed
pit viper, which is responsible for most bites in Sri Lanka
 Content
48
Section 06
Global Anti-Venom Market Analysis, by Product Type
49
Key Findings
Snake Anti-Venom
Spider Anti-venom
 Snake anti-venom segment contributed US$
 Spider anti-venom segment was valued at
XX Mn to the global anti-venom market in
US$ XX Mn in 2016 and is projected to reach
2016 and is expected to expand at the
US$ XX Mn by 2025
highest CAGR of XX% during the forecast
period from 2017 to 2025  Content
 Content
Scorpion Anti-Venom Others

 Scorpion anti-venom segment was valued at  Others anti-venom market was valued at
US$ XX Mn in 2016 and is expected to expand US$ 203.5 Mn in 2016 and is projected to
at a CAGR of XX% from 2017 to 2025 expand at a low CAGR of XX% from 2017 to
 Content 2025.
 Content
50
Introduction (2/2)
Global Anti-Venom Market, by Anti-
Venom Type
Snake Scorpion Spider

Others
Anti-Venom Anti-Venom Anti-Venom
2016 (A): US$ XX Mn 2016 (A): US$ XX Mn 2016 (A): US$ XX Mn 2016 (A): US$ XX Mn
CAGR: XX% CAGR: XX% CAGR: XX% CAGR: XX%
(2017–2025) (2017–2025) (2017–2025) (2017–2025)
2025 (F): US$ XX Mn 2025 (F): US$ XX Mn 2025 (F): US$ XX Mn 2025 (F): US$ XXMn
The snake anti-venom The scorpion anti- The spider anti-venom Others segment held
segment held XX% of venom segment held segment held XX% of XX% of the global anti-
the global anti-venom XX% of the global anti- the global anti-venom venom market in 2016,
market in 2016, and is venom market in 2016, market in 2016, and is and is expected to
expected to expand at and is expected to expected to expand at expand at a CAGR of
a CAGR of XX% from expand at a CAGR of a CAGR of XX% from XX% from 2017 to
2017 to 2025. XX% from 2017 to 2017 to 2025. 2025.
2025.
Source: TMR, 2017

51
Global Anti-Venom Market Value Share Analysis, by Product Type

Content
Figure 06: Global Anti-Venom Market Value Share Analysis, by

Product Type, 2016 and 2025 Analysis
  The snake anti-venom segment contributed XX% in 2016, and is

US$ XX Mn US$ XX Mn expected to expand at a CAGR of XX% to hold a dominant
market share of XX% by 2025 .
 Content
2016A 2025F
Snake Anti-Venom Scorpion Anti-Venom

Spider Anti-Venom Others
Source: TMR, 2017

52
Global Anti-venom Market Forecast, by Product Type

Content
Table 02: Global Anti-venom Market Value (US$ Mn) Forecast, by Product Type, 2015–2025

CAGR
Product Type 2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
(2017–25)
Snake Anti-Venom XX XX XX XX XX XX XX XX XX XX XX XX%
Scorpion Anti-
Venom
Spider Anti-venom XX XX XX XX XX XX XX XX XX XX XX XX%
Others XX XX XX XX XX XX XX XX XX XX XX XX%
Source: TMR, 2017

53
Global Anti-venom Market Analysis, by Product Type (1/2)

Content
Figure 07: Global Snake Anti-Venom Market Revenue (US$

Mn), 2015–2025 Analysis
  Snake anti-venom segment was valued

3.5 0%
670 .0
Snake Anti- at US$ XX Mn in 2016 and is projected to

3.0 0%
570 .0
reach US$ XX Mn by 2025, reflecting a

2.5 0%
Venom 470 .0
CAGR of XX%
2.0 0%
370 .0
1.5 0%
270 .0
1.0 0%  Content
170 .0
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Figure 08: Global Scorpion Anti-Venom Market Revenue

(US$ Mn),2015–2025 Analysis
 9.0 0%
 The scorpion anti-venom segment was

valued at US$ XX Mn in 2016 and is
2,5 30.0
8.0 0%
Scorpion Anti- 2,0 30.0

7.0 0%
anticipated to reach US$ XX Mn by 2025,
Venom 1,5 30.0
6.0 0% reflecting a CAGR of XX%
1,0 30.0
5.0 0%
 Content
4.0 0%
530 .0
3.0 0%
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Source: TMR, 2017

54
Global Anti-venom Market Analysis, by Product Type (2/2)

Content
Figure 09: Global Spider Anti-Venom Market Revenue (US$

Mn), 2015–2025 Analysis
 The spider anti-venom segment was

3.5 0%
670 .0
Spider Anti- valued at US$ XX Mn in 2016 and is

3.0 0%
570 .0
estimated to reach US$ XX Mn by 2025,

2.5 0%
venom 470 .0
reflecting a CAGR of XX%

2.0 0%
370 .0
1.5 0%
270 .0
1.0 0%
 Content
170 .0
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Figure 10: Global Other Anti-Venom Market Revenue (US$ Mn),

2015–2025
9.0 0%
 The others segment was valued at

Others 2,5 30.0
8.0 0%
US$ XX Mn in 2016 and is estimated

(Jelly fish,
2,0 30.0
7.0 0%
to reach US$ XX Mn by 2025,

Stingrays, etc.) 1,5 30.0
6.0 0%
reflecting a CAGR of XX%

 Content
5.0 0%
1,0 30.0
4.0 0%
530 .0
3.0 0%
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Source: TMR, 2017

55
Global Anti-venom Market Attractiveness Analysis, by Product Type

Content
Figure 11: Global Anti-venom Market Attractiveness Analysis, by

Product Type Analysis
 1.0  With a market attractiveness index of XX, snake anti-venom

segment is projected to be the most attractive product
0.9 segment in the global anti-venom market. This segment is
projected to expand at a CAGR of XX% over the forecast period
0.8
from 2017 to 2025.
0.7
 Content
0.6
CAGR Index
0.5
0.4
0.3
0.2
0.1
0.0
0.0 0.2 0.4 0.6 0.8 1.0 1.2
Market Share Index
Source: TMR, 2017

56
Key Trends
High demand for snake anti-venom 1
 Worldwide demand for snake anti-venom is about 8.0-10.0 million vials, to prevent the adverse effects of snake bites; however, only 2.0-4.0
million vials are available per year globally
 Content
57
Section 07
Global Anti-Venom Market Analysis, by Distribution

Channel
58
Key Findings
Global Anti-Venom Market, by Hospitals Global Anti-Venom Market, by Ambulatory

Surgical Center
 The hospitals segment of the global anti-
venom market was valued at US$ XX Mn in  The ambulatory surgical center segment was
2016 and is projected to expand at a CAGR of valued at US$ XX Mn in 2016 and is expected
XX% from 2017 to 2025 to reach US$ XX Mn by 2025 reflecting CAGR
of XX%
 Content
 Content
Global Anti-Venom Market, by Clinics Global Anti-Venom Market, by Others

 The clinics segment was valued at US$ XX  The other distribution channels segment is
Mn in 2016 and anticipated to expand at a likely to expand at a CAGR of XX% during the
CAGR of XX% from 2017 to 2025 forecasted period to reach US$ XX Mn by
 Content 2025
 Content
Source: TMR, 2017 59

Introduction (2/2)
Global Anti-Venom Market, by Distribution Channel
Ambulatory
Hospitals Clinics Others
Surgical Centers
2016 (A): US$ XX Mn 2016 (A): US$ XX Mn

2016 (A): US$ XX Mn CAGR: XX%
2016 (A): US$ XX Mn CAGR: XX%
CAGR: XX% (2017–2025)
CAGR: XX% (2017–2025)
(2017–2025) 2025 (F): US$ XX Mn
(2017–2025) 2025 (F): US$ XX Mn
2025 (F): US$ XX Mn
2025 (F): US$ XX Mn
The hospitals segment held XX% The clinics segment held XX% of The ambulatory surgical centers The others segment held XX%
of the global anti-venom the global anti-venom market in segment held XX% of the global of the global anti-venom
market in 2016, and is expected 2016, and is expected to expand anti-venom market in 2016, and is market in 2016, and is expected
to expand at a CAGR of XX% at a CAGR of XX% from 2017 to expected to expand at a CAGR of to expand at a CAGR of XX%
from 2017 to 2025. 2025. XX% from 2017 to 2025 from 2017 to 2025.

Global Anti-Venom Market Value Share Analysis, by Distribution Channel

Content
Figure 12: Global Anti-Venom Market Value Share Analysis,

by Distribution Channel, 2016 and 2025 Analysis
  The hospitals segment accounted for XX% market share in 2016

US$ XX Mn US$ XX Mn and is projected to lose market share to reach XX% by 2025.
The segment is likely to expand at a CAGR of XX% during the
forecast period.
 Content
2016A 2025F
Hospitals Clinics Ambulatory Surgical Centers Others

Global Anti-Venom Market Forecast, by Distribution Channel

Content
Table 03: Global Anti-Venom Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
CAGR
Distribution
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F (2017–
Channel
2025)
Hospitals XX XX XX XX XX XX XX XX XX XX XX XX%
Clinics XX XX XX XX XX XX XX XX XX XX XX XX%
Ambulatory
Surgical XX XX XX XX XX XX XX XX XX XX XX XX%
Centers


Content
Figure 13: Global Anti-Venom Market Revenue (US$ Mn)

and Y-o-Y Growth (%), by Hospitals, 2015–2025
 The hospitals segment was valued at US$

3.5 0%
670 .0
XX Mn in 2016 and is projected to reach

3.0 0%
570 .0
Hospitals 470 .0
2.5 0%
US$ XX Mn by 2025 at a CAGR of XX%

from 2017 to 2025
2.0 0%
370 .0
1.5 0%
270 .0
1.0 0%
170 .0
 Content
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Figure 14: Global Anti-Venom, Market Revenue (US$ Mn)

and Y-o-Y Growth (%), by Clinics 2015–2025
9.0 0%
 The clinics segment was valued at US$

XX Mn in 2016 and is anticipated to
2,5 30.0
8.0 0%
Clinics 2,0 30.0

7.0 0%
reach US$ XX Mn by 2025, expanding at
1,5 30.0
6.0 0% a CAGR of XX% from 2017 to 2025
5.0 0%
1,0 30.0
4.0 0%
 Content
530 .0
3.0 0%
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F


Content

and Y-o-Y Growth (%), by Ambulatory Surgical Centers,
2015–2025
 The ambulatory surgical centers
3.5 0%
670 .0
Ambulatory segment was valued at US$ XX Mn in

3.0 0%
570 .0
2016 and is estimated to reach US$ XX

2.5 0%
Surgical Centers 470 .0
Mn by 2025 at a CAGR of XX% from 2017

2.0 0%
370 .0
to 2025
1.5 0%
270 .0
1.0 0%
170 .0
0.5 0%
 Content
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F

and Y-o-Y Growth (%), by Other Distribution Channels,
2015–2025
9.0 0%
 The other distribution channels segment

was valued at US$ XX Mn in 2016 and is
2,5 30.0
8.0 0%
Others 2,0 30.0

7.0 0%
expected to reach US$ XX Mn by 2025,
1,5 30.0
6.0 0% expanding at a CAGR of XX% from 2017
5.0 0%
to 2025
1,0 30.0
4.0 0%
530 .0
 Content
3.0 0%
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F

Global Anti-Venom Market Attractiveness Analysis, by Distribution Channel

Content
Figure 72: Global Anti-Venom Market Attractiveness

Analysis, by distribution channel Analysis
1.6  Figure highlights the market share, CAGR, and segmental

market value in terms of revenue of the global anti-venom
1.4 market by each distribution channel and its relative market
attractiveness
1.2
 Content
1.0
CAGR Index
0.8
0.6
0.4
0.2
0.0
0.0 0.5 1.0 1.5 2.0 2.5
Market Share Index

Section 08
Anti-Venom Market Analysis, by Region
66
Global Anti-Venom Market Value Share Analysis, by Region

Content
Figure 18: Global Anti-Venom Market Value Share Analysis,

by Region, 2016 and 2025 Analysis
  The anti-venom market in Middle East & Africa is projected to

US$ XX Mn US$ XX Mn witness exponential growth during the forecast period. The
region is anticipated to gain market share from XX% in 2016 to
XX% by 2025.
 Content
2016A 2025F
Asia Pacific Middle East & Africa
Latin America North America
Europe

Global Anti-Venom Market Forecast, by Region

Content
Table 04: Global Anti-Venom Market Size (US$ Mn) Forecast, by Region, 2015–2025

CAGR
Region 2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F (2017–
2025)
Asia Pacific XX XX XX XX XX XX XX XX XX XX XX XX%
Middle East &

Africa
Latin America XX XX XX XX XX XX XX XX XX XX XX XX%
North America XX XX XX XX XX XX XX XX XX XX XX XX%
Europe XX XX XX XX XX XX XX XX XX XX XX XX%
Source: TMR, 2017

68

Content
Figure 19: Asia Pacific Anti-Venom Market Revenue (US$

Mn) and Y-o-Y Growth (%), 2015–2025
 The anti-venom market in Asia Pacific

3.5 0%
670 .0
was valued at US$ XX Mn in 2016 and is

3.0 0%
570 .0
Asia Pacific 470 .0

2.5 0%
projected to reach US$ XX Mn by 2025

at a CAGR of XX% from 2017 to 2025
2.0 0%
370 .0
1.5 0%
270 .0
1.0 0%
 Content
170 .0
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Figure 20: Middle East & Africa Anti-Venom Market

Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2025
9.0 0%
 The anti-venom market in MEA was

valued at US$ XX Mn in 2016 and is
2,5 30.0
8.0 0%
Middle East & 2,0 30.0

7.0 0%
anticipated to reach US$ XX Mn by 2025,
Africa 1,5 30.0
6.0 0% expanding at a CAGR of XX% from 2017
5.0 0%
to 2025
1,0 30.0
4.0 0%
530 .0
3.0 0%
 Content
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F


Content
Figure 21: Latin America Anti-Venom Market Revenue (US$

Mn) and Y-o-Y Growth (%), 2015–2025
 The market in Latin America was valued

3.5 0%
670 .0
at US$ XX Mn in 2016 and is estimated

3.0 0%
570 .0
Latin America 470 .0

2.5 0%
to reach US$ XX Mn by 2025 at a CAGR

of XX% from 2017 to 2025
2.0 0%
370 .0
1.5 0%
270 .0
1.0 0%
 Content
170 .0
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
Figure 22: North America Anti-Venom Market Revenue

(US$ Mn) and Y-o-Y Growth (%), 2015–2025
9.0 0%
 The anti-venom market in North

America was valued at US$ XX Mn in
2,5 30.0
8.0 0%
North America 2,0 30.0

7.0 0%
2016 and is expected to reach US$ XX
1,5 30.0
6.0 0% Mn by 2025, expanding at a CAGR of
5.0 0%
XX% from 2017 to 2025
1,0 30.0
 Content
4.0 0%
530 .0
3.0 0%
30. 0 2.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F


Content
Figure 23: Europe Anti-Venom Market Revenue (US$ Mn)

and Y-o-Y Growth (%), 2015–2025
 Europe anti-venom market was valued

3.5 0%
670 .0
at US$ XX Mn in 2016 and is estimated

3.0 0%
570 .0
Europe 470 .0
2.5 0%
to reach US$ XX Mn by 2025 at a CAGR

of XX% from 2017 to 2025
2.0 0%
370 .0
1.5 0%
 Content
270 .0
1.0 0%
170 .0
0.5 0%
70. 0 0.0 0%
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F

Global Anti-Venom Market Attractiveness Analysis, by Region

Content
Figure 24: Global Anti-Venom Market Attractiveness Analysis,

by Region Analysis
 1.8  XX is projected to be the most attractive market for anti-

venom, with attractiveness index of XX. It is anticipated to be
the fastest growing market and likely to account for the largest
1.6
share of the global anti-venom market.
1.4
 Content.
1.2
CAGR Index
1.0
0.8
0.6
0.4
0.2
0.0
0.0 0.5 1.0 1.5 2.0 2.5
Market Share Index
Source: TMR, 2017

72
Section 11
Asia Pacific Anti-Venom Market Analysis
73
Key Findings
Asia Pacific Anti-venom Market Analysis, by Asia Pacific Anti-Venom Market Analysis, by
Anti-venom Type Product Type
 APAC anti-venom market is valued at US$ XX  The snake anti-venom segment is expected
Mn in 2016, reflecting a CAGR of XX% during to be dominant over the forecast period
the forecast period
 Content
 Content
Asia Pacific Anti-venom Market Analysis, by Asia Pacific Anti-Venom Market Analysis, by
Country Distribution Channel
 The market in India is projected to expand at  Hospital segment accounted for XX% share of
a highest CAGR of XX% from 2017 and 2025 global anti-venom market in terms of
to reach US$ XX Mn by 2025 revenue in 2016
 Content  Content
74
Asia Pacific Anti-venom Market Overview

Content
Figure 25: Asia Pacific Anti-venom Market Size (US$ Mn) Forecast,
2017–2025 Figure 26: Asia Pacific Market Attractiveness Analysis, by Country
670 .0 9.0 0%
2.0
570 .0
8.0 0%
1.8
7.0 0%
1.6
470 .0 6.0 0% 1.4
5.0 0%
1.2
1.0
370 .0
CAGR Index
4.0 0%
270 .0 3.0 0%
0.8
2.0 0%
0.6
170 .0
1.0 0%
0.4
0.2
70. 0 0.0 0%
0.0
2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Value (US$ Mn) Y-o-Y Growth (%) Market Share Index
Analysis
 APAC region is valued at US$ XX Mn, while holding second largest market share of XX% in global anti-venom market, in 2016.
The region is expected to forecast a lucrative growth reflecting a CAGR of XX% during forecast period 2017 to 2025.
 Content
Source: TMR, 2017

75
Asia Pacific Anti-venom Market Value Share Analysis, by Anti-Venom Type

Content
Figure 27: Asia Pacific Anti-venom Market Value Share Analysis,

by Anti-Venom Type, 2016 and 2025 Analysis
  The polyvalent anti-venom segment accounted for a dominant

US$ XX Mn US$ XX Mn share of XX% in Asia Pacific market in terms of revenue, in
2016. The segment is projected to expand at a CAGR of XX%
from 2017 to 2025.
 Content
2016A 2025F
Monovalent Polyvalent
Source: TMR, 2017

76
Asia Pacific Anti-venom Market Forecast, by Anti-Venom Type

Content
Table 05: Asia Pacific Anti-venom Market Value (US$ Mn) Forecast, by Anti-Venom Type, 2017–2025

CAGR
Anti-Venom Type 2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
(2017–25)
Monovalent Anti-
Venom
Polyvalent Anti-
Venom
Source: TMR, 2017

77
Asia Pacific Anti-venom Market Value Share Analysis, by Product Type

Content

by Product Type, 2016 and 2025 Analysis
  The snake anti-venom segment accounted for XX% market

US$ XX Mn US$ XX Mn share in 2016 and is expected to gain market share of XX% by
2025
 Content
2016A 2025F
Snake Anti-Venom Scorpion Anti-Venom

Spider Anti-Venom Others
Source: TMR, 2017

78
Asia Pacific Anti-venom Market Forecast, by Product Type

Content
Table 06: Asia Pacific Anti-venom Market Value (US$ Mn) Forecast, by Product Type, 2015–2025
CAGR
Application 2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
(2017–25)
Snake Anti-
Venom
Scorpion Anti-
Venom
Spider Anti-
Venom
Source: TMR, 2017

79
Asia Pacific Anti-venom Market Value Share Analysis, by Country/Sub-region

Content

by Country, 2016 and 2025 Analysis
  India held XX% share of the anti-venom market in Asia Pacific in

US$ XX Mn US$ XX Mn terms of revenue in 2016. The market in the country is
projected to expand at a CAGR of XX% from 2017 to 2025.
 Content
2016A 2025F
India China Japan Australia & New Zealand Rest of APAC
Source: TMR, 2017

80
Asia Pacific Anti-venom Market Forecast, by Country/Sub-region

Content
Table 07: Asia Pacific Anti-venom Market Value (US$ Mn) Forecast, by Country, 2015–2025
CAGR
Country 2015A 2016A 2017E 2018F 2019F 2020F 2021F 2022F 2023F 2024F 2025F
(2017–25)
India XX XX XX XX XX XX XX XX XX XX XX XX%
China XX XX XX XX XX XX XX XX XX XX XX XX%
Japan XX XX XX XX XX XX XX XX XX XX XX XX%
Australia &
New Zealand
Rest of APAC XX XX XX XX XX XX XX XX XX XX XX XX%
Source: TMR, 2017

81
Asia Pacific Anti-venom Market Attractiveness Analysis

Content
Figure 30: Asia Pacific Anti-venom Market Attractiveness

Analysis, by Anti-Venom Type Analysis
1.5
 Polyvalent anti-venom is the most attractive anti-venom segment,
and was valued at US$ XX Mn in 2016. It is expected to reach US$ XX
1.0 Mn by 2025 at a CAGR of XX% from 2017 to 2025
 Content
CAGR Index
0.5
0.0
0.0 0.5 1.0 1.5 2.0
Market Share Index

Analysis, by Product Type Analysis
3.0  Snake anti-venom is the most attractive product segment of the anti-
2.5 venom market in Asia Pacific.
2.0  Content
1.5
CAGR Index
1.0
0.5
0.0
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Market Share Index
Source: TMR, 2017

82
Asia Pacific Anti-venom Market Attractiveness Analysis

Content

Analysis, by Distribution Channel Analysis
2.0
 Clinics followed by hospitals are the most attractive segments,
1.5 exhibiting market attractiveness index of XX and XX
respectively.
1.0
CAGR Index
 Content
0.5
0.0
0.0 0.5 1.0 1.5 2.0 2.5
Market Share Index

Analysis, by Country Analysis
2.0  XX is the most attractive country of the anti-venom market in

Asia Pacific. The segment was valued at US$ XX Mn in 2016 and
1.5
is likely to reach US$ XX Mn by 2025, expanding at a CAGR of
1.0
XX% from 2017 to 2025.
CAGR Index
0.5
 Content
0.0
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Market Share Index
Source: TMR, 2017

83
Market Trends
 Most of the governing bodies and organizations in Asia Pacific are focusing on self sufficiency
for anti-venom due to concerns over regional specificity of anti-venom as well as risk of
contamination and spread of infection as anti-venom is animal blood product. Moreover,
there is lack of clinical studies on currently available anti-venoms.
 Content
01
Working toward
solutions to gain
efficient anti-
venom stock
84
Section 13
Company Profiles
140
Competition Matrix (1/1)

CAPABILITIES POTENTIAL TO GROW
Overall Infrastructure Future
Competitors Market Position Offerings R&D focus Top Line Growth Market Share Segment growth Overall Position
Position facilities Outlook
CSL Behring LLC
 CSL Behring LLC focuses of expansion of manufacturing facilities. The company expanded its manufacturing facility is Illinois, the U.S.
in 2014 and in Australia
 Content
CAPABILITIES POTENTIAL TO GROW

Overall Infrastructure Future
Competitors Market Position Offerings R&D focus Top Line Growth Market Share Segment growth Overall Position
Position facilities Outlook
International, S.A.
Grifols
 Grifols International, S.A. engages in strategic mergers and acquisitions to expand its plasma collection units across U.S.
 Content
Rating : Strong Good Average

141
CSL Behring LLC (1/2)

Company Details Company Description
 CSL Behring is a part of CSL Group of Companies which develops biotherapeutic products for the treatment
of severe life threatening diseases and conditions
Company Name CSL Behring LLC  The company also operates one of the largest plasma collection facility chains named CSL Plasma, with
more than 150 collection centers across North America and Europe
Year of  It operates through three business segments: immunology, hematology, and specialty care
1904
Establishment  CSL Behring is one of the pioneers in anti-venom production and distribution, and holds the largest share of
the global anti-venom market
Headquarters King of Prussia, U.S. Business Overview
Anti-Venom
Revenue (2016) US$ 5,259.8 Mn Anti-Venom
Funnel Web Spider Antivenom
Black Snake Antivenom
Red Back Spider Antivenom
Employee Box Jellyfish Antivenom
~14,000 Sea Snake Antivenom
Strength (2016)
Brown Snake Antivenom
Stonefish Antivenom
Death Adder Antivenom
Key Paul Perreault, CEO Taipan Snake Antivenom
Management & MD Polyvalent Snake Antivenom
Tiger Snake Antivenom
www.cslbehring.co
Website
m Major facilities in Australia, Germany, Switzerland, United Kingdom and
the U.S
Source: Company annual report and website

142
CSL Behring LLC (2/2)

Breakdown of Net Sales (%Share), Revenue (US$ Mn) and Y-o-Y Growth (%),
SWOT Analysis by Region (2016) 2013–2016
S  Strong goodwill and market

presence
 Expertise in biotherapeutics
 Wide chain of plasma
collection centers
w  Over dependence on few

product lines
 Rising expenditure on
operations
North America Europe
2013 2014
Revenue (US$ Mn)
2015 2016
Y-o-Y Growth (%)
o
Strategic Overview
 Leverage strong pipeline of
biotherapeutics  Focus and expansion of manufacturing and distribution facilities
 Penetrate emerging markets  CSL Behring LLC expanded its manufacturing facility is Illinois, the U.S., and started operations in
such as India, China, and September 2014. In October 2014, it invested around US$ 210 Mn for establishing manufacturing site
countries in Latin America in Australia.
 In December 2015, the company started direct operations in Russia. Currently, CSL operates in over 31
T
countries, delivering products for the treatment of life threatening diseases.
 Fluctuating currency exchange
rates  Content
 Intense industry competition
and threat of new entrants
Source: TMR, 2017

143
To know more about us, please visit our website:

www.transparencymarketresearch.com
For sales queries or new topics email us on:
sales@transparencymarketresearch.com
For other queries contact:
90 State Street, Albany
NY – 12207, United States
Tel: +1-518-618-1030
T H A N K
Y O U
160

Guidance For Industry - PQR

Enviado por

Dados do documento

Título original

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Guidance For Industry - PQR

Enviado por

Direitos autorais:

Formatos disponíveis

©2017 Transparency Market Research, All Rights Reserved

Anti-Venom Market: Global Industry, Size, Share, Growth,

©2017 Transparency Market Research, All Rights Reserved

©2017 Transparency Market Research, All Rights Reserved 2

Table Of Content (1/12)

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anti-Venom Market

4.1.1. Market Definition

4.3. Market Dynamics

Table Of Content (2/12)

4.7. Polyvalent Anti-Venom Development: Overview

4.8. Scorpion Anti-Venom Development: Overview

5. Global Anti-Venom Market Analysis and Forecasts, By Anti-Venom Type

5.1. Introduction & Definition

5.2. Key Findings / Developments

5.3. Key Trends

5.4. Market Value Forecast By Anti-Venom Type , 2015–2025

5.5. Market Attractiveness By Anti-Venom Type

5.4. Key Trends

6. Global Anti-Venom Market Analysis and Forecasts, By Product Type

Table Of Content (3/12)

Table Of Content (4/12)

8.1. Key Findings

8.2. Market Value Forecast By Region

8.2.1. Asia Pacific

8.2.2. Middle East and Africa

8.2.3. Latin America

8.2.4. North America

8.3. Market Attractiveness By Country/Region

9. Asia Pacific Anti-Venom Market Analysis and Forecast

9.1.1. Key Findings

9.2. Market Value Forecast By Anti-Venom Type , 2015–2025

Table Of Content (5/12)

Table Of Content (6/12)

Table Of Content (7/12)

Table Of Content (8/12)

Table Of Content (9/12)

Table Of Content (10/12)

Table Of Content (11/12)

Table Of Content (12/12)

List of Figures (1/6)

Figure 05: Global Anti-venom Market Attractiveness Analysis, by Anti-Venom Type

List of Figures (2/6)

Figure 18: Global Anti-Venom Market Attractiveness Analysis, by Distribution Channel

Figure 25: Global Anti-Venom Market Attractiveness Analysis, by Region

Figure 27: Asia Pacific Anti-Venom Market Attractiveness Analysis, by Country

List of Figures (3/6)

List of Figures (4/6)

Figure 55: Latin America Anti-venom Market Attractiveness Analysis, by Country

Figure 57: North America Anti-Venom Market Attractiveness Analysis, by Country

List of Figures (5/6)

Figure 67: Europe Anti-Venom Market Attractiveness Analysis, by Country

Figure 72: Europe Anti-venom Market Attractiveness Analysis, by Anti-Venom Type

Figure 73: Europe Anti-venom Market Attractiveness Analysis, by Product Type

Figure 74: Europe Anti-venom Market Attractiveness Analysis, by Distribution Channel

Figure 75: Europe Anti-venom Market Attractiveness Analysis, by Country

Figure 76: Breakdown of Net Sales (2015), by Segments: CSL Behring

List of Figures (6/6)

Figure 82: Breakdown of Net Sales (2015), by Segments: Vacsera